MML Investors Services LLC Sells 34,502 Shares of DexCom, Inc. (NASDAQ:DXCM)

MML Investors Services LLC decreased its position in DexCom, Inc. (NASDAQ:DXCM) by 52.7% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 30,975 shares of the medical device company’s stock after selling 34,502 shares during the period. MML Investors Services LLC’s holdings in DexCom were worth $2,077,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Migdal Insurance & Financial Holdings Ltd. bought a new stake in DexCom in the 2nd quarter worth $25,000. Sachetta LLC increased its holdings in DexCom by 255.2% during the 2nd quarter. Sachetta LLC now owns 238 shares of the medical device company’s stock valued at $27,000 after purchasing an additional 171 shares during the period. Riverview Trust Co raised its position in DexCom by 100.4% during the 3rd quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock valued at $31,000 after purchasing an additional 232 shares during the last quarter. DT Investment Partners LLC lifted its holdings in DexCom by 492.2% in the 2nd quarter. DT Investment Partners LLC now owns 379 shares of the medical device company’s stock worth $43,000 after buying an additional 315 shares during the period. Finally, RPg Family Wealth Advisory LLC bought a new stake in shares of DexCom in the 3rd quarter worth approximately $57,000. 97.75% of the stock is owned by hedge funds and other institutional investors.

DexCom Trading Down 1.0 %

Shares of NASDAQ DXCM opened at $76.41 on Tuesday. The firm’s 50 day moving average price is $73.91 and its 200-day moving average price is $83.75. DexCom, Inc. has a 52-week low of $62.34 and a 52-week high of $142.00. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46. The company has a market cap of $29.85 billion, a PE ratio of 45.75, a P/E/G ratio of 2.46 and a beta of 1.12.

Insider Buying and Selling

In other DexCom news, EVP Sadie Stern sold 4,259 shares of the business’s stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total value of $318,275.07. Following the completion of the transaction, the executive vice president now owns 71,192 shares of the company’s stock, valued at approximately $5,320,178.16. The trade was a 5.64 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.30% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. Sanford C. Bernstein upped their target price on DexCom from $82.00 to $86.00 and gave the company an “outperform” rating in a report on Friday, October 25th. Canaccord Genuity Group boosted their price target on shares of DexCom from $89.00 to $99.00 and gave the company a “buy” rating in a research report on Monday, December 9th. StockNews.com lowered shares of DexCom from a “buy” rating to a “hold” rating in a report on Saturday, November 2nd. JPMorgan Chase & Co. upped their target price on DexCom from $75.00 to $85.00 and gave the stock a “neutral” rating in a report on Friday, October 25th. Finally, Royal Bank of Canada decreased their target price on DexCom from $120.00 to $115.00 and set an “outperform” rating for the company in a research report on Friday, October 25th. Seven equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $98.00.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.